Tolerability of the COX-1/COX-2 Inhibitor Lornoxicam in the Treatment of Acute and Rheumatic Pain

Abstract

Aim: To assess the safety of lornoxicam with particular focus on gastrointestinal (GI) events. Methods: Data on adverse drug reactions (ADRs) were pooled from 60 comparative studies of lornoxicam. Results: A total of 6420 patients received lornoxicam, 1192 received placebo and 3770 received a comparator analgesic. ADRs were reported by 21% of lornoxicam-treated patients, with GI events the most frequent (14 vs 8% with placebo). Across 15 studies that compared lornoxicam (n = 1287) with another NSAID (n = 1010), there was a reduced risk of a GI ADR with lornoxicam (0.78 [95% CI: 0.64–0.96]; p = 0.017). Conclusion: Lornoxicam was well tolerated with the type of GI events observed consistent with the known safety profile of NSAIDs.

KEYWORDS:

• acute pain
• COX inhibitors
• gastrointestinal toxicity
• lornoxicam
• NSAIDs
• oxicams
• rheumatic pain

Disclosure

These data were previously presented at the International Association for the Study of Pain (IASP) 15th World Congress on Pain, Buenos Aires, Argentina, 6–11 October 2014.

Financial & competing interests disclosure

JP Marstein is a former employee of Takeda Pharmaceuticals International GmbH. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

Medical writing support was provided by Andy Bond, Spirit Medical Communications Ltd, funded by Takeda Pharmaceuticals International GmbH.

Ethical conduct of research

The authors state that they have obtained appropriate institutional review board approval or have followed the principles outlined in the Declaration of Helsinki for all human or animal experimental investigations. In addition, for investigations involving human subjects, informed consent has been obtained from the participants involved.

Additional information

Funding

JP Marstein is a former employee of Takeda Pharmaceuticals International GmbH. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed. Medical writing support was provided by Andy Bond, Spirit Medical Communications Ltd, funded by Takeda Pharmaceuticals International GmbH.